Dr. Ravi Rao has been a member of DBV’s Board of Directors since 2021. He is currently Chief Medical Officer at Oxford Biomedica and at Sitryx Therapeutics. He previously held positions as Head of R&D and Chief Medical Officer at Swedish Orphan Biovitrum (Sobi), Chief Medical Officer at Aeglea Biotherapeutics and Vice President in Research and Development and Medical Affairs at GlaxoSmithKline as well as senior leadership positions at Roche. Before joining the pharmaceutical industry, he was an academic rheumatologist at Imperial College and a post-doctoral fellow at Harvard University. Dr. Rao is a Member of the Royal College of Physicians, London, and an Honorary Member of the Faculty of Pharmaceutical Medicine.